Open AccessPHARMACOECONOMIC ANALYSIS OF ANTIPARASITIC DRUGS FOR THE TREATMENT OF GIARDIASIS IN ADULT PATIENTS
Author(s) -
K Adekenova,
О В Маслова,
E G Tolokonnikov,
S Kunzhan
Publication year - 2020
Publication title -
izvestiâ nacionalʹnoj akademii nauk respubliki kazahstan. seriâ biologičeskaâ i medicinskaâ
Language(s) - English
Resource type - Journals
eISSN - 2518-1629
pISSN - 2224-5308
DOI - 10.32014/2020.2519-1629.2
Subject(s) - medicine , giardia , drug , intensive care medicine , diarrhea , pharmacotherapy , pharmacology , veterinary medicine
This article presents the pharmacoeconomic rationale for the treatment of giardiasis in adult patients. Giardia is one of the most common pathogenic eukaryotic microorganisms and the most common cause of diarrhea in the world. Currently, there are a number of drugs recommended for the treatment of giardiasis that differ in terms of effectiveness and safety, as well as the cost of therapy. Therefore, it is necessary to conduct a clinical and econo-mic analysis in order to comparatively assess the quality of drug therapy for giardiasis.The use of treatment regimens for giardiasis using the domestic drug "Sausalin" is economically feasible given the high level of eradication and the safety profile of the new drug. When conducting a repeated course of therapy for one patient with the drug "Sausalin", the savings is up to 25% in comparison with the "Ornisid".The effectiveness of the original drug "Sausalin" is discussed.